NGL Fine-Chem peers

·Pharma & HealthChart ›

Companies like NGL Fine-Chemlatest year

NGL Fine-ChemNGLFINE · FY26 · this company
Market cap₹1,613
P/E33.51×
Sales growth+33.6%
ROE15.7%
Syncom Formulations (India)SYNCOMF · FY26
Open ›
Market cap₹1,911
P/E25.10×
Sales growth+7.4%
ROE20.2%
Jagsonpal PharmaceuticalsJAGSNPHARM · FY26
Open ›
Market cap₹1,547
P/E36.09×
Sales growth+9.3%
ROE16.7%
Hester BiosciencesHESTERBIO · FY26
Open ›
Market cap₹1,909
P/E33.21×
Sales growth−8.2%
ROE16.5%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NGLFINE₹2,610.60

NGL Fine-Chem Limited

· Pharma & Health
₹ CrorePeersSYNCOMFJAGSNPHARMHESTERBIOAMRUTANJANWINDLASINDOCOSAIPARENTMcap ₹1,613 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
NGLFINE
FY26
SYNCOMF
FY26
JAGSNPHARM
FY26
HESTERBIO
FY26
Peer
Average
Valuation — at last close
P/E33.51×◆ 25.10×36.09×33.21×31.46× +7%
P/B4.90×◆ 4.61×5.60×5.30×5.17× -5%
EV/EBITDA◆ 23.07×23.24×24.80×24.21×24.09× -4%
Market Cap₹1,613 Cr₹1,911 Cr₹1,547 Cr₹1,909 Cr₹1,789 Cr -10%
Growth
Revenue CAGR 3Y21.68%◆ 29.69%6.66%7.72%14.69% +48%
Revenue CAGR 5Y——8.85%◆ 9.19%9.02%
Net Income CAGR 3Y32.91%◆ 56.16%17.26%27.04%33.49% -2%
Revenue YoY (latest Q)◆ 33.57%7.38%9.28%-8.16%2.83% +1085%
Net Income YoY (latest Q)99.09%57.71%0.13%◆ 459.27%172.37% -43%
Profitability
EBITDA Margin14.51%15.83%20.22%◆ 26.05%20.70% -30%
Net Income Margin9.61%15.63%15.00%◆ 17.28%15.97% -40%
Return on Common Equity15.74%◆ 20.19%16.69%16.50%17.79% -12%
Return on Capital Employed14.96%◆ 18.08%17.99%12.87%16.31% -8%
Return on Assets9.83%◆ 16.14%14.48%8.64%13.09% -25%
Credit & Quality
Total Debt/Equity0.33×◆ 0.00×0.00×0.51×0.17× +94%
Interest Coverage11.89×◆ 61.38×47.31×6.20×38.30× -69%
Scale — latest FY
Revenue / Total Income₹501 Cr₹489 Cr₹287 Cr₹333 Cr₹370 Cr +36%
Net Income₹48.1 Cr₹76.4 Cr₹43.1 Cr₹57.5 Cr₹59 Cr -18%
Total Assets₹545 Cr₹534 Cr₹317 Cr₹678 Cr₹509 Cr +7%
EPS₹77.9₹0.81₹6.4₹67.57₹24.93 +213%
Book Value per Share₹532.91₹4.41₹41.24₹423.46₹156.37 +241%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.